PARP inhibitorPhase 3 trialInvestigational
PARP inhibitor
How it works
Blocks the repair of DNA damage in cancer cells, causing them to die.
Cancer types
Prostate Cancer— Patients with BRCA mutations
Efficacy
Studies show that PARP inhibitors can improve overall survival in around 30% of patients with BRCA mutations.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| PARP Inhibitor TSL-1502 Shows Promise in Advanced Breast Cancer | Breast Cancer | phase-2 | The objective response rates were 36.0% in the 350 mg group, 55.6% in the 500 mg group, and 40.0% in the chemotherapy group. | Source → |
| Tirapazamine and PARP Inhibitor Combination Shows Promise in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Testing Radiation, Immunotherapy, and PARP Inhibitor in Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| New Tool Helps Predict Outcomes for Ovarian Cancer Patients on PARP Inhibitor Therapy | Ovarian Cancer | observational | Patients with OC who received first-line PARPi maintenance treatment showed improved PFS (median PFS: 48.53 months) and OS. | Source → |
| Testing Trastuzumab Deruxtecan for Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Combining PARP Inhibitors and Platinum May Enhance Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| PARP Inhibitor Talazoparib Shows Promise in Treating Breast and Ovarian Cancers | Breast Cancer | review | Talazoparib has the highest potency (IC = 0.57 nM), which is 4-10 times lower than that of other PARP inhibitors. | Source → |
| DRG2 levels predict response to PARP inhibitors in prostate cancer cells | Prostate Cancer | lab-study | — | Source → |
| New Test for Cancer Patients May Help with PARP Inhibitor Therapy | Breast Cancer | lab-study | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | review | — | Source → |
| PARP Inhibitor Resistance Linked to BRCA1 Gene Mutations | Ovarian Cancer | lab-study | — | Source → |
| Combining Cancer Treatments May Improve Lung Cancer Outcomes | Lung Cancer | lab-study | Tumor doubling times increased to 1.6-fold (H446) and 2.2-fold (H69) under combination treatment. | Source → |
| Mutations in Prostate Cancer Tissue Affect PARP Inhibitor Therapy | Prostate Cancer | lab-study | — | Source → |
| Spliceosome Gene Mutations in Leukemia Linked to PARP Inhibitor Sensitivity | Leukemia | lab-study | — | Source → |
| PARP Inhibitor Resistance in Pancreatic Cancer | Pancreatic Cancer | observational | Reversions were significantly associated with rapid resistance to PARPi treatment (median PFS, 3.7 vs. 12.5 months; P = 0.001) and poor overall survival (median OS, 6.2 vs. 23.0 months; P < 0.0001). | Source → |
| Combining Hormonal Therapies with PARP Inhibitors for Prostate Cancer | Prostate Cancer | phase-3 | Emerging data suggested that the radiographic progression-free survival (rPFS) was significantly longer in the PARP inhibitor combined with NHT group versus the placebo plus NHT group. | Source → |
| Researchers Investigate PARP Inhibitor Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Olaparib Can Be Re-Administered After Chemotherapy | Breast Cancer | observational | — | Source → |
| New Therapy Combination Shows Promise for Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| Combining Two Treatments May Help Some Ovarian Cancer Patients | Ovarian Cancer | lab-study | The sequential combination of PLK1 inhibitor and PARP inhibitor drastically reduces HGSOC cell survival. | Source → |
| PARP Inhibitor Treatment Patterns in Ovarian Cancer | Ovarian Cancer | observational | Median progression-free survival of first line treatment after PARP inhibitor was 9.6, 3.5 and 4.6 months for platinum doublet, single agent platinum and non-platinum chemotherapy, respectively. | Source → |
| PARP Inhibitor Use in Gynecological Cancer Patients Compared | Ovarian Cancer | observational | — | Source → |
| PARP Inhibitor Maintenance Treatment and Chemotherapy Response in Ovarian Cancer | Ovarian Cancer | observational | An objective response was found in 13.0%, 26.2%, and 41.9% of the patients with platinum-free intervals <6 months, 6-12 months, and >12 months, respectively. | Source → |
| Cost-effectiveness of PARP inhibitors in cancer treatment | Ovarian Cancer | review | — | Source → |
| Rucaparib and Nivolumab Tested as Maintenance Treatment for Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| PARP Inhibitor Resistance Found in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| PARP Inhibitor Resistance Emerges in Cancer Cells | Leukemia | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.